Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $48,048.10 in Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 51,115 shares of the company’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $0.94, for a total transaction of $48,048.10. Following the completion of the transaction, the insider now owns 326,904 shares of the company’s stock, valued at $307,289.76. This trade represents a 13.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Jonathan Zalevsky also recently made the following trade(s):

• On Tuesday, November 19th, Jonathan Zalevsky sold 7,785 shares of Nektar Therapeutics stock. The stock was sold at an average price of $1.01, for a total transaction of $7,862.85.

Nektar Therapeutics Trading Down 1.3 %

NASDAQ NKTR traded down $0.01 during trading hours on Friday, reaching $0.93. The company’s stock had a trading volume of 1,787,229 shares, compared to its average volume of 1,795,548. The business has a 50-day simple moving average of $1.19 and a 200 day simple moving average of $1.24. Nektar Therapeutics has a 52 week low of $0.46 and a 52 week high of $1.93. The stock has a market cap of $171.23 million, a PE ratio of -1.11 and a beta of 0.57.

Institutional Investors Weigh In On Nektar Therapeutics

A number of hedge funds have recently added to or reduced their stakes in NKTR. Samlyn Capital LLC acquired a new stake in shares of Nektar Therapeutics in the 2nd quarter worth about $11,728,000. Eventide Asset Management LLC increased its stake in shares of Nektar Therapeutics by 24.8% in the third quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock valued at $12,220,000 after purchasing an additional 1,870,904 shares during the period. Millennium Management LLC raised its holdings in shares of Nektar Therapeutics by 56.1% during the second quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company’s stock valued at $5,778,000 after buying an additional 1,674,924 shares during the last quarter. Nantahala Capital Management LLC boosted its position in shares of Nektar Therapeutics by 66.0% during the second quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock worth $5,096,000 after buying an additional 1,634,046 shares during the period. Finally, State Street Corp boosted its position in shares of Nektar Therapeutics by 11.9% during the third quarter. State Street Corp now owns 3,345,733 shares of the biopharmaceutical company’s stock worth $4,349,000 after buying an additional 355,759 shares during the period. 75.88% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. HC Wainwright assumed coverage on Nektar Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $6.50 target price on the stock. BTIG Research restated a “buy” rating and set a $4.00 price objective on shares of Nektar Therapeutics in a research note on Monday, September 30th. Finally, Piper Sandler assumed coverage on Nektar Therapeutics in a research report on Monday, November 4th. They issued an “overweight” rating and a $7.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $4.10.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.